Progest Tablet

Dydrogesterone is an orally-active progestogen which produces a complete secretory endometrium in an estrogen-primed uterus thereby providing protection against the increased risk for endometrium hyperplasia and carcinogenesis induced by estrogens. It is indicated in all cases of endogenous progesterone deficiency. Dydrogesterone has no estrogenic, no androgenic, no thermogenic, no anabolic and no corticoid activity.

Always take Presentation 10 mg tablet exactly as your doctor has prescribed.

Presentationerone deficiencies:

• Threatened miscarriage: 40 mg (four tablets) at once, then 10 mg (one tablet) every eight hours until symptoms remit.
• Habitual miscarriage: 10 mg (one tablet) twice daily until the twentieth week of pregnancy.
• Dysmenorrhoea: 10 mg (one tablet) twice daily from day 5 to day 25 of the menstrual cycle.
• Endometriosis: 10 mg (one tablet) two or three times daily from day 5 to day 25 of the cycle or continuously.
• Dysfunctional bleeding (to arrest bleeding): 10 mg (one tablet) twice daily for five to seven days. Presentation should be given with oestrogen.
• Dysfunctional bleeding (to prevent bleeding): 10 mg (one tablet) twice daily from day 11 to day 25 of the cycle. Presentation should be given with oestrogen.
• Amenorrhoea: An oestrogen once daily from day 1 to day 25 of the cycle, together with 10 mg Presentation twice daily from day 11 to day 25 of the cycle.
• Irregular cycles: 10 mg (one tablet) twice daily from day 11 to day 25 of the cycle.
• Infertility due to luteal insufficiency: 10 mg (one tablet) daily from day 14 to day 25 of the cycle. The treatment should be continued for at least 6 consecutive cycles. It is advisable to continue this treatment during the first month of any pregnancy using the doses stated with respect to habitual miscarriage.
• Luteal support as part of an Assisted Reproductive Technology (ART) treatment: 10 mg three times daily (three tablets daily) starting at the day of oocyte retrieval and continuing for 10 weeks if pregnancy is confirmed.

Hormone Replacement Therapy: In combination with continuous oestrogentherapy, take one tablet daily for 14 consecutive days of a 28 day cycle. In combination with cyclical oestrogen therapy take one tablet daily during the last 12 to 14 days of oestrogen therapy.

For doctors: If endometrial biopsies or ultrasound reveal inadequate Presentationational response, 20 mg Dydrogesterone should be prescribed.

For patients: If you are not sure what type of oestrogen therapy you are on, talk to your Doctor before taking Presentation. There is no relevant use of Dydrogesterone before menarche. The safety and efficacy of Dydrogesterone in adolescents aged 12 to 18 years has not been established.

No interaction studies have been performed.

• Hypersensitivity to the active substance or to any of the excipients
• Known or suspected progestogen dependent neoplasms
• Undiagnosed vaginal bleeding
• If used to prevent endometrial hyperplasia (in women using estrogens)
• Thrombophlebitis or thromboembolic disorders.
• Cerebrovascular or coronary artery disease, or a past history of these conditions.
• Hepatic disease or dysfunction, a history of cholestatic jaundice or pruritus of pregnancy and in Dubin-Johnson syndrome and Rotor syndrome.
• History of herpes in pregnancy.
• Sickle cell anaemia.
• Benign or malignant liver tumours which develop during the use of oral contraceptives

The most commonly reported adverse drug reactions of patients treated with Progest in clinical trials of indications without oestrogen treatment are

• Migraines/headache,
• Nausea,
• Menstrual disorders and
• Breast pain/tenderness.

So far there were no indications of a harmful effect of Dydrogesterone use during pregnancy. Dydrogesterone is excreted in the milk of nursing mothers. A risk to the breastfed child cannot be excluded. Dydrogesterone should not be used during breast-feeding. There is no evidence that Dydrogesterone decreases fertility.

Before initiating Progest treatment for abnormal bleeding the etiology for the bleeding should be clarified. Breakthrough bleeding and spotting may occur during the first months of treatment. If breakthrough bleeding or spotting appears after some time on therapy, or continues after treatment has been discontinued, the reason should be investigated, which may include endometrial biopsy to exclude endometrial malignancy.

If one of the following disorders occurs during use for the first time or gets worse, stopping the treatment should be considered.

• Severe headache, migraine or symptoms that may indicate cerebral ischemia.
• Marked increase in blood pressure.
• Occurrence of venous thromboembolism (VTE)

In cases of habitual or threatened abortion, the viability of the fetus should be ascertained. It is also necessary to monitor during treatment whether the pregnancy is still progressing and whether the embryo is still alive. Treatment with Progest has infrequently been associated with alterations in liver function, sometimes accompanied by clinical symptoms. Thus, Progest should be used with caution in patients with acute liver disease or a history of liver disease as long as liver function tests have failed to return to normal. In cases of severe hepatic impairment treatment should be discontinued.

Patients with a history of depression must be carefully monitored; if severe depression recurs, treatment with Progest must be stopped.

Progest was well tolerated after oral dosing (maximum daily dose is 360 mg). No reports of ill effects from overdose have been recorded. If a large overdose is discovered within two or three hours and treatment seems desirable, gastric lavage is recommended. There are no specific antidotes and treatment should be symptomatic. Aforementioned information is also applicable for overdosing in children.

Female Sex hormones

Store at below 30°C in a dry place protected from light. Keep out of reach of children.